Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-791

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-791). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 791 52 Master Bottle Label Approval Rev A 01 22)

Label for Losartan Potassium Tablets USP 100 mg, oral film-coated tablets. The package contains 30 tablets. The label includes storage instructions to keep at 20°-25°C with permitted excursions, keep container tightly closed, and protect from light. The labeler is Northwind Health Company, LLC.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over study months between Losartan Potassium and Atenolol. The x-axis represents study months up to 66, and the y-axis shows the percentage of patients up to 16%. Data indicates adjusted risk reduction with Losartan Potassium versus Atenolol, with statistical significance noted.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over months of study between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months up to 66, and the y-axis shows the percentage of patients. A note indicates an adjusted risk reduction of 25% with Losartan Potassium, p=0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol event rates. It shows hazard ratios with 95% confidence intervals for primary composite events and stroke (fatal/non-fatal) across various subgroups, including age, gender, race, ISH status, diabetes, and history of cardiovascular disease. The plot indicates whether outcomes favor Losartan Potassium or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line chart comparing the percentage of patients with an event over 48 months for Losartan Potassium versus Placebo. The chart shows cumulative event incidence with a risk reduction of 16.1% favoring Losartan Potassium, with statistical significance indicated by p=0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium, showing its molecular configuration including the potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.